Vimarsana
Biggest News Aggregation in the World

Marek Kania News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Marek Kania. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Marek Kania Today - Breaking & Trending Today

Choi stars as South Korea sweep short-track medals at Lake Placid 2023 - Vimarsana News

Choi stars as South Korea sweep short-track medals at Lake Placid 2023

A strong South Korean team starring three-time Olympic champion Choi Min-jeong swept the medals on the opening day of short-track speed skating competition at the International University Sports Federation Winter World University Games here.

Hutchmed China to shift strategy toward advanced assets in pipeline - Vimarsana News

Hutchmed China to shift strategy toward advanced assets in pipeline

Hutchmed Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business. The biopharmaceutical company... | November 15, 2022

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer - Vimarsana News

HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

08.08.2022 - — Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for regulatory submissions underway in the U.S., Europe and Japan — — Results to be submitted to ... Seite 1

HUTCHMED drug in colorectal cancer trial meets primary endpoint - Vimarsana News

HUTCHMED drug in colorectal cancer trial meets primary endpoint

A trial to look at the use of a drug targeting refractory metastatic colorectal cancer (CRC) has met its primary endpoint.

Market movers: Hutchmed (China) rises after cancer treatment update - Vimarsana News

Market movers: Hutchmed (China) rises after cancer treatment update

AIM listed Hutchmed (China) Limited pleased shareholders with news that the global phase three trial evaluating the investigational use of 'fruquintinib'...